Publications Database

Troost P. et al. (2005)

Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.

Journal of the American Academy of Child and Adolescent Psychiatry

44(11), pp. 1137-1144

Read Abstract (New Window)

Tsai H. et al. (2012)

Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review.

International Journal of Clinical Practice

November, 66(11), pp. 1056–1078.

Read Abstract (New Window)

Tuchman R. F. (2004)

AEDs and psychotropic drugs in children with autism and epilepsy.

Mental Retardation and Developmental Disabilities Research Reviews

10(2), pp. 135-138

Read Abstract (New Window)

Tyrer P. et al. (2008)

Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.

Lancet

371(9606), pp. 57-63.

Read Abstract (New Window)

Umbricht D. et al. (2016)

A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder.

Neuropsychopharmacology

Read Abstract (New Window)

Unis A. et al. (2002)

A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism.

Journal of the American Academy of Child and Adolescent Psychiatry

41(11),

Read Abstract (New Window)

Unwin G. L. , Deb S. (2008)

Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians' consensus survey.

American Journal of Mental Retardation

113(1), pp. 19-31

Read Abstract (New Window)

Urbano M. R. et al. (2014)

A trial of d-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder.

Clinical Neuropharmacology

May, 37(6), pp. 69-72.

Read Abstract (New Window)

Urbano M. R. et al. (2015)

A trial of d-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders.

Journal of Neuropsychiatry and Clinical Neurosciences

Spring, 27(2), pp. 133-138.

Read Abstract (New Window)

US Food and Drug Administration (2007)

Methylphenidate.

Bethesda, MD: US National Library of Medicine.

Read Full (New Window)

US National Library of Medicine (2006)

Leuprolide.

Bethesda, MD: US National Library of Medicine.

Read Full (New Window)

Uvebrant P. , Bauziene R. (1994)

Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure related benefits.

Neuopediatrics

25(6), pp. 284-289

Read Abstract (New Window)

Valdovinos M. G. et al. (2002)

Multimodal evaluation of risperidone for destructive behavior: functional analysis, direct observations, rating scales, and psychiatric impressions.

Experimental and Clinical Psychopharmacology

10(3), pp. 268-275

Read Abstract (New Window)

Valicenti-McDermott M. R. , Demb H. D. (2006)

Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.

Journal of Child and Adolescent Psychopharmacology

16(5), pp. 549-560

Read Abstract (New Window)

Varni J. W. et al. (2012)

Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: A post hoc analysis of two controlled trials.

Clinical Therapeutics

34(4), pp. 980-992.

Read Abstract (New Window)

Vasa R. A. et al. (2014)

A systematic review of treatments for anxiety in youth with autism spectrum disorders.

Journal of Autism and Developmental Disorders

December, 44(12), pp. 3215-3229.

Read Abstract (New Window)

Vasa R. A. et al. (2016)

Assessment and treatment of anxiety in youth with autism spectrum disorders.

Pediatrics

February, 137

Read Full (New Window)

Veenstra-VanderWeele J. et al.

Arbaclofen in children and adolescents with autism spectrum disorder: A randomized, controlled, phase 2 trial.

Neuropsychopharmacology

Read Abstract (New Window)

Veenstra-VanderWeele J. (2010)

Increase in valproic acid levels during riluzole treatment in an adolescent with autism.

Journal of Child and Adolescent Psychopharmacology

20(2), pp. 163-165

Read Extract (New Window)

Vercellino F. et al. (2001)

Open-label risperidone treatment of 6 children and adolescents with autism

Canadian Journal of Psychiatry

August, 46(6), pp.559-560.